Get the Stockscreener App
0.5929
3.59%
-0.0221
After Hours:
.61
0.0171
+2.88%
Longeveron Inc stock is traded at $0.5929, with a volume of 500.53K.
It is down -3.59% in the last 24 hours and down -19.55% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.615
Open:
$0.611
24h Volume:
500.53K
Relative Volume:
1.12
Market Cap:
$12.65M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.0886
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
-5.89%
1M Performance:
-19.55%
6M Performance:
-51.80%
1Y Performance:
-71.50%
1-Day Range:
$0.585
$0.64
1-Week Range:
$0.585
$0.6876
52-Week Range:
$0.585
$2.24
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5929 | 13.12M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.04 | 115.56B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.26 | 75.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.02 | 60.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.76 | 55.48B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.55 | 43.51B | 447.02M | -1.18B | -906.14M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - The Manila Times
Longeveron (NASDAQ: LGVN) CSO, CMO to Join CVCT Forum Panels on Cell Therapy Trials - Stock Titan
Can Longeveron Inc. stock continue upward trendWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Longeveron (LGVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Longeveron receives Canadian patent for stem cell therapy By Investing.com - Investing.com Nigeria
Perhaps timely catching Longeveron Inc (LGVN) would be a good idea - Setenews
Longeveron receives Canadian patent for stem cell therapy - Investing.com
Longeveron granted Canadian patent for method of using stem cells to treat non-ischemic dilated cardiomyopathy - MarketScreener
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - The Manila Times
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial By Investing.com - Investing.com South Africa
Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025 - TipRanks
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) sees MRI inflammation drop in 13 of 14 brain regions at week 39 - Stock Titan
Longeveron (NASDAQ:LGVN) Shares Up 3% – Should You Buy? - Defense World
Longeveron announces board member resignation - MSN
Is Longeveron Inc. stock a buy in volatile marketsJuly 2025 Price Swings & Safe Swing Trade Setups - moha.gov.vn
Longeveron Inc. (LGVN) Jumps 6% in Pre-market: What’s Driving the Move? - Stocks Telegraph
Will Longeveron Inc. stock attract more institutional investorsJuly 2025 Selloffs & Entry Point Confirmation Signals - BỘ NỘI VỤ
Longeveron Inc. (LGVN) 5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take off with Longeveron Inc (LGVN): Get ready for trading - Setenews
What data driven models say about Longeveron Inc.’s futureJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Longeveron Inc. (LGVN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Longeveron to present Alzheimer's treatment data at CTAD 2025 By Investing.com - Investing.com Nigeria
Longeveron to present Alzheimer’s treatment data at CTAD 2025 By Investing.com - Investing.com Australia
Will Longeveron Inc. stock remain a Wall Street favorite2025 Dividend Review & Community Shared Stock Ideas - newser.com
Longeveron to present Alzheimer’s treatment data at CTAD 2025 - Investing.com
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) Presenting Laromestrocel CLEAR MIND Data at CTAD 2025 - Stock Titan
Why analysts upgrade Longeveron Inc. stock2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Visualizing Longeveron Inc. stock with heatmapsJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
What drives Longeveron Inc stock priceHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
What dividend safety score for Longeveron Inc. stockWeekly Risk Report & Entry Point Confirmation Signals - newser.com
How Longeveron Inc. stock compares to growth peersJuly 2025 Big Picture & Expert Verified Movement Alerts - Fundação Cultural do Pará
Is Longeveron Inc. stock recession proof2025 Volume Leaders & High Accuracy Investment Signals - Fundação Cultural do Pará
Longeveron Faces Nasdaq Delisting Notice for Stock Price - MSN
Will Longeveron Inc. stock continue dividend increasesPortfolio Growth Summary & Weekly High Return Stock Forecasts - newser.com
Longeveron secures patent for stem cell therapy targeting aging frailty By Investing.com - Investing.com Nigeria
Longeveron announces resignations of two board members By Investing.com - Investing.com Australia
Longeveron granted U.S. patent for administration of MSCs - TipRanks
How does Longeveron Inc (LGVN) change from a tortoise to a hare? - Setenews
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
2.67%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):